Iterum Therapeutics plc
ITRM
$0.9966
-$0.0534-5.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 35.44% | 1.75% | 49.70% | 29.99% | 13.64% |
| Total Depreciation and Amortization | -83.77% | -73.53% | -49.40% | -25.70% | -2.78% |
| Total Amortization of Deferred Charges | -2.18% | 82.50% | -1.20% | -0.60% | 0.04% |
| Total Other Non-Cash Items | 204.51% | 136.43% | -137.58% | -136.66% | -140.03% |
| Change in Net Operating Assets | -560.77% | -283.59% | -556.06% | -56.04% | 19.56% |
| Cash from Operations | 31.93% | -14.97% | -61.18% | -73.67% | -112.91% |
| Capital Expenditure | 84.62% | 96.55% | 101.47% | 79.03% | 79.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -22.01% | 114.98% | -14.98% | 167.04% | 66.55% |
| Cash from Investing | -21.97% | 115.85% | -14.78% | 168.65% | 67.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,481.33% | 1,426.54% | 819.70% | 1,100.00% | 138.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,481.33% | 1,426.54% | 819.70% | 1,100.00% | 156.88% |
| Foreign Exchange rate Adjustments | -22.95% | -335.00% | -228.00% | -90.00% | -22.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 220.19% | 154.70% | -294.84% | 35.15% | -135.29% |